Cargando…
Effect of GLP-1 agonists on weight loss in patients with polycystic ovary syndrome and obesity: A single-center study
BACKGROUND: Weight loss of >5% in patients with polycystic ovary syndrome and obesity (PCOS–O) is believed to improve underlying drivers of the syndrome. Weight loss facilitated by GLP-1 agonists in patients with PCOS–O is not well characterized. In this single-center retrospective study, we dete...
Autores principales: | Srinivasan, Dushyanth, Lofton, Holly F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661916/ https://www.ncbi.nlm.nih.gov/pubmed/37990710 http://dx.doi.org/10.1016/j.obpill.2022.100016 |
Ejemplares similares
-
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists
por: Cena, Hellas, et al.
Publicado: (2020) -
The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome
por: Bednarz, Krzysztof, et al.
Publicado: (2022) -
The inositols and polycystic ovary syndrome
por: Kalra, Bharti, et al.
Publicado: (2016) -
Effects of aerobic exercise on plasma lipoproteins in overweight and obese women with polycystic ovary syndrome
por: Abazar, Elaheh, et al.
Publicado: (2015) -
Bone morphogenetic proteins and the polycystic ovary syndrome
por: van Houten, E Leonie AF, et al.
Publicado: (2013)